Nintedanib (NIN) is one of the FDA-approved tyrosine kinase inhibitor drugs used to treat
idiopathic pulmonary fibrosis (IPF). This study aimed to formulate a long-circulating injection …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disorder caused by
abnormal extracellular matrix deposition, which results in increasing dyspnea and loss of …

Nintedanib (NIN) and pirfenidone are the only approved drugs for the treatment of Idiopathic
Pulmonary Fibrosis (IPF). However, NIN and pirfenidone have low oral bioavailability and …

Nintedanib is an approved tyrosine kinase inhibitor for the treatment of idiopathic pulmonary
fibrosis (IPF); however, the bioavailability is low due to low solubility. In this study, nintedanib …

Idiopathic pulmonary fibrosis is a chronic lung disease that is characterized by progressive
abnormal reprogramming following injury of the pulmonary structure. In this study, we …

Idiopathic pulmonary fibrosis (IPF) is a fatal respiratory disease characterized by chronic,
progressive scarring of the lung parenchyma, leading to an irreversible decline in lung …

Purpose The purpose of this study was to develop inhalable pirfenidone (PFD)
nanoparticles for the delivery of the medicine to specific alveolar epithelial cells (AECs) in …

Introduction Idiopathic pulmonary fibrosis (IPF), a life-threatening interstitial lung disease, is
characterized by excessive activation and proliferation of fibroblasts and epithelial …

Idiopathic pulmonary fibrosis (IPF) is an irreversible interstitial lung disease with a poor
prognosis. However, there are currently few drugs available for its treatment. Nintedanib is …

Idiopathic pulmonary fibrosis is a progressive, fatal lung disease with poor survival. The
advances made in deciphering this disease have led to the approval of different antifibrotic …